<PAGE>
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Dated February 24, 2000
PHOENIX INTERNATIONAL LIFE SCIENCES INC.
----------------------------------------
(Translation of registrant's name into English)
2350 Cohen Street
-----------------
Saint Laurent, Quebec Canada H4R 2N6
------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ______ Form 40-F X (commenced in calendar
----- year 1998)
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ____ No X
---
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): ______________
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
PHOENIX INTERNATIONAL LIFE SCIENCES INC.
----------------------------------------
(Registrant)
Date: February 24, 2000 By: /s/ David Moszkowski
--------------------- ------------------------
David Moszkowski
Senior Vice President and
Chief Financial Officer
<PAGE>
Exhibit 99.1
PHOENIX INTERNATIONAL STREAMLINES GLOBAL
CLINICAL RESEARCH OPERATIONS
Dr. Susan Thornton to head up worldwide Phase II-IV Business
Montreal, February 22, 2000 - Phoenix International Life Sciences Inc. (NASDAQ:
PHXI; TSE: PHX), one of the world's leading contract research organizations,
today announced the consolidation of all worldwide clinical research activities
into one business unit. The Global Clinical Research (Phase II-IV) unit will
operate under the direction of Dr. Susan Thornton, currently Head of Clinical
Research, Americas. This consolidation is being undertaken in response to the
increased focus of the pharmaceutical industry on global drug development.
"This initiative supports our ongoing focus to improve the operating efficiency
and performance of our global Phase II-IV operations," stated Ian Lennox, CEO,
Phoenix International. Mr. Lennox added, "Dr. Thornton has the expertise and
leadership experience to drive the growth and development of our worldwide
Clinical Research operations."
Prior to joining Phoenix International, Dr. Thornton held various positions in
drug development and licensing at SmithKline-Beecham and Merck. Since 1992, Dr.
Thornton has played a key role in the growth of the clinical research business
for IBRD-Rostrum Global and subsequently Phoenix International. In 1998, she was
appointed President and COO for Phoenix International's Phase II-IV Clinical
Research business.
About Phoenix International
Phoenix International is one of the world's leading contract research
organizations. The Company is a global leader in early stage pharmaceutical
development and has a growing presence in late stage pharmaceutical development.
Headquartered in Montreal, Quebec, the Company employs over 2,000 people in 19
countries around the world. Phoenix International is on the worldwide web at
www.pils.com.
This release contains "forward-looking" statements regarding future results and
events, including statements regarding expected future revenues, earnings and
growth rates and goals and operating plans of management. Phoenix's actual
future results may differ significantly from the results discussed in the
forward-looking statements contained in this release. Factors that may cause
such a difference include, but are not limited to: the inability of Phoenix to
win new business at the levels required; the cancellation or delay of contracts;
risks associated with the management of growth and the ability to attract and
retain employees; risks of integrating newly acquired businesses; competition;
any claims for patent infringement; unanticipated costs in connection with Year
2000 conversion; the ability to obtain future financing; adverse regulatory
developments; foreign exchange rate fluctuations; and uncertainty surrounding
the Euro.
<PAGE>
FOR MORE INFORMATION, PLEASE CONTACT:
MEDIA:
RICHARD GAREAU
Director of Communications
Phoenix International Life Sciences Inc.
Tel: (514) 333-0033, extension 4638
E-mail: [email protected]
ANALYST CONTACT:
DAVID MOSZKOWSKI, C.A.
Senior Vice President and Chief Financial Officer
Phoenix International Life Sciences Inc.
Tel: (514) 333-0033 Fax: (514) 335-8351
E-mail: [email protected]
